While GLP-1 drugs are generally well-tolerated, there are a handful of rare but serious adverse events that deserve attention. These are not common — the vast majority of people taking GLP-1 drugs have no serious complications — but they are important to understand before you start therapy.
Gallbladder Disease: The Most Confirmed Serious Risk
This is the best-substantiated serious risk. Clinical trials have consistently shown an increased incidence of cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) in people taking GLP-1 drugs, especially semaglutide and liraglutide.
The mechanism is understood: rapid weight loss + reduced gallbladder motility = increased bile cholesterol saturation, which promotes stone formation. The more weight you lose, the higher the risk.
Incidence: In the SUSTAIN and SURMOUNT trials, cholecystitis/cholelithiasis occurred in approximately 1–3% of semaglutide recipients vs. 0.5–1% of placebo recipients. Dulaglutide showed similar patterns.
Symptoms to watch for
- Sudden sharp pain in the right upper abdomen or under the right shoulder
- Pain that gets worse after eating fatty foods
- Nausea and vomiting with abdominal pain
- Pain that persists for 30 minutes or more
If you develop severe right upper quadrant pain with nausea, go to an emergency room or call your doctor immediately. Untreated cholecystitis can progress to acute pancreatitis or bile duct obstruction.
Risk reduction strategies
- Gradual weight loss: Slower weight loss reduces gallstone formation risk. Rapid drop of >3 lbs/week increases risk.
- Ursodeoxycholic acid (UDCA): Some clinicians prescribe prophylactic ursodiol during rapid weight loss to reduce stone formation. Discuss with your doctor if you're losing weight rapidly.
- Regular imaging if high-risk: If you have risk factors (age >40, female, family history), an ultrasound before starting GLP-1 may be justified.
Pancreatitis: Real Concern, Unclear Causation
Acute pancreatitis (inflammation of the pancreas) is listed in the FDA warning for GLP-1 drugs. There is a theoretical mechanism (GLP-1 receptors on pancreatic cells, altered gastric motility leading to increased intraductal pressure), and there are case reports, but the epidemiological evidence from large trials is mixed.
The LEADER trial (liraglutide, ~9,000 patients): 18 cases of acute pancreatitis on liraglutide vs. 23 on placebo. The SUSTAIN 6 trial (semaglutide, ~3,300 patients): similar incidence in both groups. A 2024 meta-analysis of >55,000 GLP-1-treated patients found no increase in pancreatitis risk compared to control.
Most gastroenterology societies now consider the pancreatitis risk "theoretical but unconfirmed" based on trial data. The FDA warning persists out of abundance of caution. People with a history of pancreatitis should generally avoid GLP-1 drugs unless specifically cleared by their doctor.
Warning signs: stop and call your doctor if you experience
- Severe, persistent abdominal pain, especially radiating to the back
- Pain that doesn't improve and is worse than typical GLP-1 nausea
- Nausea and vomiting that accompanies the abdominal pain
- Pain that worsens after eating
If you develop severe persistent abdominal pain while on a GLP-1 drug, stop the medication and contact your healthcare provider or emergency room immediately. Untreated pancreatitis can be life-threatening.
Thyroid C-Cell Tumors: The Black Box Warning Explained
All GLP-1 receptor agonists carry a black box warning — the FDA's most serious drug warning — about thyroid C-cell tumors. This can sound alarming, so it's worth understanding what the evidence actually shows.
In studies in rats and mice, GLP-1 receptor agonists caused thyroid C-cell hyperplasia and eventually medullary thyroid carcinoma (MTC). This is a well-established finding in rodents.
Here's why the human relevance is uncertain:
- Rodents have far more GLP-1 receptors in thyroid C-cells than humans do. The exposure-response relationship may simply not translate.
- Human clinical trials have not found increased thyroid cancer rates. No case of drug-induced MTC in a human has been confirmed from GLP-1 use.
- Semaglutide's SURMOUNT and STEP trials — involving tens of thousands of patients — have not identified a thyroid cancer signal.
Who the contraindication applies to
Despite the uncertain human risk, the drugs are contraindicated in people with:
- A personal history of medullary thyroid carcinoma (MTC)
- A family history of MTC
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Medullary thyroid carcinoma is rare — only ~3–4% of all thyroid cancers. Even if GLP-1 drugs do have a small effect in humans, the absolute risk is thought to be very low. The contraindication exists as a precaution for high-risk individuals, not as a population-wide concern.
Kidney Effects: Usually Protective, Occasionally Harmful
The kidney story with GLP-1 drugs is nuanced and generally more positive than the other risks on this page.
The protective angle
In patients with type 2 diabetes and existing chronic kidney disease, GLP-1 drugs — particularly semaglutide — have shown kidney-protective effects in clinical trials. The FLOW trial was stopped early in 2024 because semaglutide was so clearly beneficial that it was deemed unethical to continue giving some patients placebo. Semaglutide reduced serious kidney disease progression by 24%.
The dehydration risk
For people without pre-existing kidney disease, the main kidney concern is indirect: severe nausea, vomiting, and reduced fluid intake can lead to dehydration. Dehydration reduces blood flow to the kidneys and can cause acute kidney injury, especially in people taking NSAIDs, diuretics, or certain blood pressure medications.
During dose escalation — when nausea is most common — make a conscious effort to stay hydrated even if you're not feeling thirsty. If you're vomiting repeatedly and can't keep fluids down for more than 24 hours, contact your doctor.
Who Should Not Take GLP-1 Drugs
Based on the risk profile above, GLP-1 drugs are contraindicated or require special caution in these groups:
Hard Contraindications & High-Risk Groups
Putting the Risks in Perspective
It's important to keep these serious risks in context. For most people on GLP-1 drugs:
- Pancreatitis does not occur at a higher rate than in the general population
- Gallbladder disease is the most common serious complication, but still affects <1–3% of users
- Thyroid cancer has not been confirmed in any human taking GLP-1 drugs
- Kidney function often improves, especially in diabetic patients
The drugs have been studied in hundreds of thousands of people, and the serious adverse event rate remains low. However, screening for contraindications and being vigilant for warning symptoms is prudent.
More on GLP-1 Downsides
Serious risks are one category of downside. Others include common side effects, cost, weight regain, and the injection requirement. Read our full guides:
- Injection Requirement & Needle Anxiety
- Nausea & GI Side Effects
- Muscle Loss & Lean Mass
- Cost & Insurance Coverage
- Weight Regain After Stopping